Dr. Vibhu Jha
Assistant Professor
- Area
- School of Pharmacy & Medical SciencesFaculty of Life Sciences

Biography
Dr Vibhu Jha is an Assistant Professor in Computational Drug Design at the Institute of Cancer Therapeutics, University of Bradford, UK. His research focuses on structure-based drug discovery, molecular modelling, artificial intelligence, and machine learning approaches to investigate protein–ligand and protein–protein interactions for the development of novel therapeutics, particularly in oncology.
Dr Jha obtained his B. Pharm. degree from Chhattisgarh Swami Vivekananda Technical University (CSVTU), India, and his M.S. Pharm. (Medicinal Chemistry) from the National Institute of Pharmaceutical Education and Research (NIPER), India. During his master's studies, he conducted research at the CSIR–Central Drug Research Institute (CDRI), Lucknow, on the design and synthesis of antidiabetic agents. Prior to his PhD, he served as a Junior Lecturer at ITM University, Gwalior.
He completed his PhD with Excellent Honours at the University of Pisa, Italy (2017–2021), where he employed molecular modelling and virtual screening approaches to identify novel anticancer compounds. During his doctoral studies, he also spent six months as a visiting researcher at the Institute of Cancer Therapeutics, gaining experience in medicinal chemistry and translational drug discovery.
Following his PhD, Dr Jha worked as a Research Scientist at the University of Dundee, UK, on structure-based design of antitubercular and antimalarial agents. He subsequently joined the University of Gothenburg, Sweden, as a postdoctoral researcher, where his work expanded into computational and theoretical biochemistry, biomolecular simulations, teaching, and student supervision.
Dr Jha has authored more than 25 peer-reviewed publications and maintains active international collaborations with research groups across the United Kingdom, Sweden, Spain, India, Italy, and Jordan. His current research interests span computational chemical biology, biomolecular simulations, AI-assisted therapeutic discovery, and mechanistic studies of disease-relevant biomolecular systems. He currently supervises /co-supervises PhD and Master's researchers and has been awarded Fellowship of the Higher Education Academy (FHEA) in recognition of his contributions to teaching and academic practice.
Research
My research lies at the interface of computational chemical biology, medicinal chemistry, and biochemistry, with a focus on understanding biomolecular interactions and accelerating therapeutic discovery. I employ a broad range of computational approaches, including molecular docking, virtual screening, molecular dynamics simulations, enhanced sampling methods, and binding free-energy analyses to investigate protein–ligand and protein–protein interactions, elucidate molecular mechanisms of disease, and support the rational design of novel therapeutics. These studies are complemented through close collaborations involving medicinal chemistry, biochemical characterization, and experimental validation.
Current research interests include:
• Cancer metabolism and enzyme-targeted therapeutics: Development of selective modulators of one-carbon metabolism enzymes and aldehyde dehydrogenase (ALDH) isoforms implicated in tumour progression, stemness, and therapeutic resistance.
• Signal transduction and kinase-targeted therapeutics: Structural and mechanistic studies of EGFR and Src family kinases and associated signalling networks involved in tumour progression, metastasis, and therapeutic resistance, alongside the discovery of small-molecule modulators targeting disease-relevant signalling pathways.
• Cytoskeleton-targeted drug discovery: Discovery and mechanistic characterization of novel tubulin-targeting agents and multi-target anticancer compounds through integrated computational, medicinal chemistry, and biochemical approaches.
• Neurodegenerative diseases and drug repurposing: Investigation of cholinergic signalling pathways, acetylcholinesterase modulation, and disease-associated biomolecular networks to identify novel therapeutic and repurposing opportunities for Alzheimer's disease and related disorders.
• Network and systems pharmacology: Integration of biological networks, multi-omics data, and artificial intelligence approaches to identify disease-associated pathways, uncover polypharmacological mechanisms, and support translational therapeutic discovery.
In parallel, I develop and apply AI and machine learning methodologies to enable virtual screening, molecular property prediction, hit prioritisation, drug repurposing, and rational therapeutic design across oncology and neurodegenerative disease research.
Professional activities
Awards (8)
- 2-year Postdoc research funding at the University of Gothenburg, Sweden (1 April 2022)
- 2-year research position approved at the University of Dundee (1 March 2021)
- 2-year Postdoc research funding at the University of Gothenburg, Sweden (1 March 2021)
- Excellent Grade with Honours in PhD (1 February 2021)
- Fully-funded international PhD position (1 September 2017)
- Qualified NIPER-JEE with All India Rank 315 (1 June 2013)
- Qualified Graduate Pharmacy Aptitude Test (GPAT) with All India Rank 541 (1 May 2013)
- B. Pharm. Gold Medalist (1 May 2012)
Education (4)
- Chhattisgarh Swami Vivekananda Technical University, Bhilai, India - B. Pharm.
- Department of Pharmacy, University of Pisa, Italy - PhD in Pharmaceutical Science
- National Institute of Pharmaceutical Education and Research, Raebareli, India - M. S. Pharm. (Medicinal Chemistry)
- Institute of Cancer Therapeutics, University of Bradford - Visiting PhD
Employment (3)
- University of Gothenburg, Sweden - Postdoctoral Researcher in Computational Drug Discovery (1 April 2022)
- University of Dundee, UK - Researcher in Molecular Modeling (15 March 2021)
- ITM University, Gwalior, India - Assistant Professor in Pharmaceutical Chemistry (13 July 2015)
Professional associations (2)
- Chhattisgarh State Pharmacy Council, Raipur, India, Regulation of pharmacy practice, pharmacy profession and pharmacy education in the country
- Royal Society of Chemistry (MRSC), Member
Publications
Article (1)
Molecular structural investigations of quinoxaline derivatives through 3D-QSAR, molecular docking, ADME prediction and pharmacophore modeling studies for the search of novel antimalarial agent
Achal Mishra, Vibhu Jha, Harish Rajak (2022)
Book chapter (2)
Implication of drug repurposing in the identification of antibacterial agents
Vibhu Jha, Leif A. Eriksson (2023) Drug Repurposing . De Gruyter.
6 Implication of drug repurposing in the identification of antibacterial agents
Vibhu Jha;Leif A. Eriksson (2023) Drug Repurposing.
Conference publication (2)
Abstract 1820: N,N-diethylaminobenzaldehyde-based small molecules to probe aldehyde dehydrogenase as target in prostate cancer
Elisabet Batlle Rocafort; Ali I. Ibrahim; Maria Sadiq; Sneha Smarakan; Vibhu Jha; Tiziano Tuccinardi; Fiona Frame; Norman Maitland; Rafael Jiménez Aguilar; Raquel Pequerul Pavón; Xavier Parés Casampera; Goreti Ribeiro Morais; Jaume Farrés Vicen; Klaus Pors (2022) Proceedings: AACR Annual Meeting.
Virtual screening platform on structure based pharmacophore hypothesis to design potential human LDH-A inhibitors against cancer
Vibhu Jha (2018) Joint Event on 8th World Congress on Chemistry and Organic Chemistry & International Conference on Biomedicine & Pharmacotherapy.
Other publication (1)
Binding Analysis and Structure-Based Design of Tricyclic Coumarin-Derived MTHFD2 Inhibitors as Anticancer Agents: Insights from Computational Modeling
Jha, V.;Holmelin, F.L.;Eriksson, L.A. (2022) SSRN.
Peer reviewed journal (27)
Machine learning-driven computational drug repurposing to identify new tubulin inhibitors against cancer
Neelima Neelima;Hussein Elrewey;Sneha Smarakan;Amalia Ruiz;Muhammad Wahajuddin;Gaurav Joshi;Vibhu Jha (2026) Bioorganic and Medicinal Chemistry.
Machine learning-driven computational drug repurposing to identify new tubulin inhibitors against cancer
Neelima Neelima, Hussein Elrewey, Sneha Smarakan, Amalia Ruiz, Muhammad Wahajuddin, Gaurav Joshi, Vibhu Jha, (2026) BIOORGANIC & MEDICINAL CHEMISTRY.
Unraveling the Binding Mode of TSC2–Rheb through Protein Docking and Simulations
Berith F. Pape, Shraddha Parate, Leif A. Eriksson, Vibhu Jha (2025) Biochemistry.
Computational Network Pharmacology, Molecular Docking, and Molecular Dynamics to Decipher Natural Compounds of Alchornea laxiflora for Liver Cancer Chemotherapy
Jain, N. K., Chandrasekaran, B., Khazaleh, N., Jain, H. K., Lal, M., Joshi, G., & Jha, V. (2025) Pharmaceuticals.
Design and development of sulfenylated 5-aminopyrazoles as inhibitors of acetylcholinesterase and butyrylcholinesterase: exploring the implication for Aβ
1-42aggregation inhibition in Alzheimer's diseaseRani, P.;Chahal, S.;Ranolia, A.;Kiran;Kumar, D.;Kataria, R.;Kumar, P.;Singh, D.;Duhan, A.;Jha, V.;Wahajuddin, M.;Joshi, G.;Sindhu, J. (2025) Rsc Medicinal Chemistry.
Unraveling the Binding Mode of TSC2-Rheb through Protein Docking and Simulations
Pape, B.F.;Parate, S.;Eriksson, L.A.;Jha, V. (2025) Biochemistry.
Design and development of sulfenylated 5-aminopyrazoles as inhibitors of acetylcholinesterase and butyrylcholinesterase: exploring the implication for Aβ1-42 aggregation inhibition in Alzheimer
Rani P, Chahal S, Ranolia A, Kiran, Kumar D, Kataria R, Kumar P, Singh D, Duhan A, Jha V, Wahajuddin M, Joshi G, Sindhu J. (2025) Rsc Medicinal Chemistry.
Design and Synthesis of Topoisomerases-Histone Deacetylase Dual Targeted Quinoline-Bridged Hydroxamates as Anticancer Agents
Joshi, G., Yadav, U. P., Rafiq, Z., Grewal, P., Kumar, M., Singh, T., Jha, V., Sharma, P., Eriksson, L. A., Srinivas, L., Dahibhate, N. L., Srivastava, P., Bhutani, P., Mishra, U. K., Sharon, A., Banerjee, U. C., Sharma, N., Chatterjee, J., Tikoo, K., Singh, S., Kumar, R. (2025) Journal of Medicinal Chemistry.
Repurposing of USFDA-approved drugs to identify leads for inhibition of acetylcholinesterase enzyme: a plausible utility as an anti-Alzheimer agent
Dr.Kapil Kumar Goel;Sandhya Chahal;Devendra Kumar;Dr Shivani Jaiswal;Nidhi Nainwal;Rahul Singh;Shriya Mahajan;Pramod Rawat;Savita Yadav;Prachi Fartyal;Gazanfar Ahmad;Vibhu Jha;ashish ranjan dwivedi (2024) Rsc Medicinal Chemistry.
Exploring the Artificial Intelligence and Its Impact in Pharmaceutical Sciences: Insights Toward the Horizons Where Technology Meets Tradition
Shruti Bharadwaj;Kumari Deepika;Asim Kumar;Shivani Jaiswal;Shaweta Miglani;Damini Singh;Prachi Fartyal;Roshan Kumar;Shareen Singh;Mahendra Pratap Singh;Abhay M. Gaidhane;Bhupinder Kumar;Vibhu Jha (2024) Chemical Biology and Drug Design.
Dess–Martin periodinane-mediated oxidation of the primary alcohol of cytidine into a carboxylic acid
Serre, A.R.E;Jha, V.;Rivault, A.;Eriksson, L.A.;Ribeiro Morais, G.;Falconer, R.A. (2024) Organic and Biomolecular Chemistry. 22
Selectivity analysis of diaminopyrimidine-based inhibitors of MTHFD1, MTHFD2 and MTHFD2L
Vibhu Jha;Leif A. Eriksson (2024) Scientific Reports.
Binding Modes of Xanthine-Derived Selective Allosteric Site Inhibitors of MTHFD2.
Jha V;Eriksson LA; (2023) ChemistryOpen. 12
Binding Analysis and Structure-Based Design of Tricyclic Coumarin-Derived MTHFD2 Inhibitors as Anticancer Agents: Insights from Computational Modeling.
Jha V;Holmelin FL;Eriksson LA; (2023) Acs Omega. 8
Design and Synthesis of Thionated Levofloxacin: Insights into a New Generation of Quinolones with Potential Therapeutic and Analytical Applications.
Ibrahim AIM;Abul-Futouh H;Bourghli LMS;Abu-Sini M;Sunoqrot S;Ikhmais B;Jha V;Sarayrah Q;Abulebdah DH;Ismail WH; (2022) Current Issues in Molecular Biology. 44
Expansion of the 4-(Diethylamino)benzaldehyde Scaffold to Explore the Impact on Aldehyde Dehydrogenase Activity and Antiproliferative Activity in Prostate Cancer
Ali I M Ibrahim, Elisabet Batlle, Smarakan Sneha, Rafael Jiménez, Raquel Pequerul, Xavier Parés, Till Rüngeler, Vibhu Jha, Tiziano Tuccinardi, Maria Sadiq, Fiona Frame, Norman J Maitland, Jaume Farrés, Klaus Pors (2022) Journal of Medicinal Chemistry. 65
Molecular structural investigations of quinoxaline derivatives through 3D-QSAR, molecular docking, ADME prediction and pharmacophore modeling studies for the search of novel antimalarial agent
Achal Mishra;Vibhu Jha;Harish Rajak (2022) Journal of the Indian Chemical Society.
Abstract 1820: N,N-diethylaminobenzaldehyde-based small molecules to probe aldehyde dehydrogenase as target in prostate cancer
Elisabet Batlle Rocafort;Ali I. Ibrahim;Maria Sadiq;Sneha Smarakan;Vibhu Jha;Tiziano Tuccinardi;Fiona Frame;Norman Maitland;Rafael Jiménez Aguilar;Raquel Pequerul Pavón;Xavier Parés Casampera;Goreti Ribeiro Morais;Jaume Farrés Vicen;Klaus Pors (2022) Cancer Research.
Discovery of a new ATP-citrate lyase (ACLY) inhibitor identified by a pharmacophore-based virtual screening study.
Jha V;Galati S;Volpi V;Ciccone L;Minutolo F;Rizzolio F;Granchi C;Poli G;Tuccinardi T; (2021) Journal of Biomolecular Structure and Dynamics. 39
Design, Synthesis, Biological Evaluation and In Silico Study of Benzyloxybenzaldehyde Derivatives as Selective ALDH1A3 Inhibitors.
Ibrahim AIM;Ikhmais B;Batlle E;AbuHarb WK;Jha V;Jaradat KT;Jiménez R;Pequerul R;Parés X;Farrés J;Pors K; (2021) Molecules. 26
Discovery of Monoacylglycerol Lipase (MAGL) Inhibitors Based on a Pharmacophore-Guided Virtual Screening Study.
Jha V;Biagi M;Spinelli V;Di Stefano M;Macchia M;Minutolo F;Granchi C;Poli G;Tuccinardi T; (2020) Molecules. 26
Three-Dimensional Interactions Analysis of the Anticancer Target c-Src Kinase with Its Inhibitors.
Jha V;Macchia M;Tuccinardi T;Poli G; (2020) Cancers. 12
Computationally driven discovery of phenyl(piperazin-1-yl)methanone derivatives as reversible monoacylglycerol lipase (MAGL) inhibitors.
Poli G;Lapillo M;Jha V;Mouawad N;Caligiuri I;Macchia M;Minutolo F;Rizzolio F;Tuccinardi T;Granchi C; (2019) Journal of Enzyme Inhibition and Medicinal Chemistry. 34
MOLECULAR DOCKING STUDIES OF CYCLOOXYGENASE ENZYME (COX-2) INHIBITORY ACTIVITY OF MAIN ACTIVE CONSTITUENTS OF CALENDULA OFFICINALIS
(2019) International Journal of Research in Ayurveda and Pharmacy.
Development of a Fingerprint-Based Scoring Function for the Prediction of the Binding Mode of Carbonic Anhydrase II Inhibitors.
Poli G;Jha V;Martinelli A;Supuran CT;Tuccinardi T; (2018) International Journal of Molecular Sciences. 19
Structure-based Pharmacophore Hypothesis to Design Potential Human LDH-A Inhibitors against Cancer
(2018) Asian Journal of Biomedical and Pharmaceutical Sciences.
Synthesis, pharmacological evaluation and molecular docking studies of pyrimidinedione based DPP-4 inhibitors as antidiabetic agents
(2018) Journal of Molecular Structure.